A global pulmonary arterial hypertension registry: Is it needed? Is it feasible? Pulmonary vascular disease: The global perspective

Chest

Volumn 137, Issue 6 SUPPL., 2010, Pages 95S-101S

  Gomberg Maitland, Mardi ^a   Michelakis, Evangelos D ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; PROSTACYCLIN; WARFARIN;

CLINICAL TRIAL; DEMOGRAPHY; DEVELOPING COUNTRY; DRUG COST; HUMAN; INCIDENCE; OXYGEN BREATHING; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SURVIVAL;

EID: 77953300691     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-3008     Document Type: Review

References (16)

1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361(9368):1533-1544.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223. (Pubitemid 17137857)
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
4. Abenhaim L, Moride Y, Brenot F, et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335(9):609-616.
5. Hyduk A, Croft JB, Ayala C, Zheng K, Mensah GA. Pulmonary hypertension and surveillance - United States, 1980-2002. MMWR Surveill Summ. 2005;54(5)1-28.
6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France:results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
7. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132(2):373-379.
8. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104-109.
9. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30(6):1103-1110.
10. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
11. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation. 2008;118(17):1758-1766.
12. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007;153(6):1037-1047.
13. Lo B, Field MJ; Committee on Conflict of Interest in Medical Research, Education, and Practice; Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: The National Academies Press; 2009.
14. Russo H. HIPAA Creating privacy protection that works. Caring. 2001;20(5):12-16, 18, 20-22.
15. Fullbrook S. Legal principles of confidentiality and other public interests: Part 1. Br J Nurs. 2007;16(14):874-875.
16. Drolet BC, Johnson KB. Categorizing the world of registries. J Biomed Inform. 2008;41(6):1009-1020.